Current Indication for HSCT

1
Current Indication for HSCT

• EBMT Activity Survey
• Numbers of HSCT
• Trend over time
• by disease
• Differences between countries
• by disease
• Coefficient of variation

2
(No Transcript)
3
(No Transcript)
4
(No Transcript)
5
Final data
6
(No Transcript)
7
(No Transcript)
8
(No Transcript)
9
(No Transcript)
10
(No Transcript)
11
(No Transcript)
12
(No Transcript)
13
(No Transcript)
14
(No Transcript)
15
(No Transcript)
16
(No Transcript)
17
(No Transcript)
18
(No Transcript)
19
(No Transcript)
20
(No Transcript)
21
(No Transcript)
22
(No Transcript)
23
(No Transcript)
24
(No Transcript)
25
(No Transcript)
26
(No Transcript)
27
Neuroblastoma auto
28
(No Transcript)
29
Fig. 3 c
30
Fig. 3 d
31
Fig. 3 e
32
Fig. 3 f
33
(No Transcript)
34
(No Transcript)
35
(No Transcript)
36
(No Transcript)
37
(No Transcript)
38
(No Transcript)
39
(No Transcript)
40
(No Transcript)
41
CV lt 50

• Allogeneic HSCT
• CML allo, 1st cP, not 1st cP
• AML, ALL 1st CR, not 1st CR
• MDS
• NHL
• Autologous HSCT
• HD, NHL
• MM
• Ewing's sarcoma
• Neuroblastoma

42
Conclusions

• Indications for HSCT can be defined
• Changing field
• Population, not individual patient
• Team Decisions ?